Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working Group
|
|
- Walter Tyler
- 5 years ago
- Views:
Transcription
1 Critical Reviews in Oncology/Hematology 82 (2012) Early detection, prevention and management of cutaneous adverse events due to sorafenib: Recommendations from the Sorafenib Working Group Sergio Bracarda a,, Enzo Maria Ruggeri b, Marcello Monti c, Marco Merlano d, Alessandro D Angelo e, Francesco Ferraù e, Enrico Cortesi f, Armando Santoro g a Ospedale San Donato USL8, Medical Oncology, Department of Oncology, Arezzo, Italy b Ospedale Belcolle, Viterbo, Italy c Università degli Studi di Milano e Istituto Clinico Humanitas, Milano, Italy d ASO Santa Croce e Carle, Cuneo, Italy e Ospedale Civico San Vincenzo, Taormina (ME), Italy f Policlinico Umberto I, Roma, Italy g Istituto Clinico Humanitas, Milano, Italy Accepted 17 August 2011 Contents 1. Introduction Overview of Sorafenib Sorafenib-related cutaneous events Hand-foot skin reaction Erythema Itching Follicular rash Xerosis or skin dryness Keratocanthoma (KA) and squamous cell carcinoma (SCC) Recommendations for the prevention and management of sorafenib-related cutaneous reactions Hand-foot skin reaction Erythema Itching Follicular rash Xerosis or skin dryness KA and SCC Conclusions Authors contributions Conflict of interest statement Reviewers Acknowledgments Appendix Appendix References Biographies Corresponding author. Tel.: ; fax: address: sergio.bracarda@usl8.toscana.it (S. Bracarda) /$ see front matter 2011 Elsevier Ireland Ltd. All rights reserved. doi: /j.critrevonc
2 S. Bracarda et al. / Critical Reviews in Oncology/Hematology 82 (2012) Abstract Cutaneous adverse events commonly reported with tyrosine kinase inhibitors (TKIs) in the treatment of malignancies, represent an important clinical concern since they can limit the optimal use of these novel drugs. Although there are numerous reports in the literature of these events there are no practical guidelines on how they should be managed. The Sorafenib Working Group (SWG) was established with the objective of developing recommendations to allow the early detection, prevention and management of cutaneous adverse events in everyday clinical practice. The SWG was a multidisciplinary team made up of experts in the field who were closely involved in the sorafenib clinical development program. This review provides an overview of the nature and incidence of cutaneous adverse events which manifest with sorafenib treatment and provides recommendations for their early detection and effective management in clinical practice Elsevier Ireland Ltd. All rights reserved. Keywords: Sorafenib; Cutaneous adverse events; Hand-foot skin reaction; Prevention; Guidelines; Targeted therapy 1. Introduction Advances in the understanding of cell molecular biology, leading to the discovery and elucidation of signal transduction processes and specific cell receptors, prompted investigators to develop novel anticancer agents directed against cell-specific pathways at a molecular level, including gene expression, growth regulation, cell cycle control, apoptosis, and angiogenesis. In the clinical settings targeted agents have shown considerable efficacy levels in a range of tumor types, particularly in terms of progression-free survival (PFS) and overall survival (OS), as well as acceptable, albeit diverse, toxicity profiles [1,2]. Even so, the introduction into the clinical practice of these targeted agents has raised a number of issues not just regarding the correct assessment of their efficacy, but also how best to manage their diverse toxicity profiles mainly characterized by low-grade and potentially long-term events [3,4]. In terms of severity, frequency and type, toxicities caused by targeted agents differ substantially from those of conventional cytotoxic chemotherapeutic regimens [5]. Adverse events with these new targeted agents are not life-threatening events which require major supportive care and/or treatment discontinuation, but rather a series of less frequent inconveniences and disturbances which nevertheless can have a major negative effect on quality of life by limiting activities of daily living (ADL) [6]. Assessment of the impact of the disease and its treatment on health-related quality of life may not only influence the choice of treatment but also can sometimes prevent the administration of recommended optimal doses. In addition, it is important to be aware of the long-term effects of these new agents both on the type and incidence of adverse events as well as the effects of these events on patient compliance to treatment. Initially this caused uncertainty among physicians who were unaccustomed to managing these unusual adverse events and often meant that the therapeutic approach was suboptimal [5]. Of note, a recent paper by Bellmunt et al. has extensively discussed the management of adverse events associated with sorafenib treatment in patients with renal cell carcinoma (RCC) [7]. The aim of this paper is to provide practicing physicians with the specific information necessary to diagnose, prevent and manage the dermatological events related to the treatment with sorafenib, with particular reference to the hand-foot skin reaction (HFSR). Although there are numerous reports in the literature of these events and some practical guidelines have been published, a general consensus upon this topic has not been reached. This may be attributed, at least in part, to the lack of prospective trials investigating the management of these dermatological events. To address this, the Sorafenib Working Group (SWG) was established. This group is made up of eight Italian investigators: seven oncologists with experience in managing and treating cancer patients and one dermatologist with particular experience in the management of targeted therapy-related adverse events. The SWG aims to collect the experience of each clinician, in order to develop detailed practical guidelines for the prevention and the management of dermatological adverse events associated with sorafenib. Importantly, all eight specialists had previously participated in pivotal trials as part of the sorafenib clinical development program and had built up long-term experience on its use in everyday clinical practice. Based on this experience, management of cutaneous events was carried out using preparations with proven efficacy but employing the commonly used agents that can potentially lead to adverse skin events, with care [8]. 2. Overview of Sorafenib Sorafenib (Nexavar, Bayer HealthCare AG) is an oral multikinase inhibitor with antiangiogenic and proapoptotic activity. Preclinical in vitro and in vivo tumor models demonstrate that sorafenib is a potent inhibitor of the C-RAF and B-RAF kinases, as well as the RTKs VEGF receptor- 2 (VEGFR-2) and platelet-derived growth factor receptor- [9]. Inhibition of these kinases gives the drug a dual mechanism of action its anti-proliferative activity directly on tumor cell targets and indirectly through the inhibition of angiogenesis [10]. Sorafenib was approved by the FDA in 2005 for the treatment of advanced renal cell carcinoma (RCC) and subsequently results of a phase III randomized, placebo-controlled trial (SHARP trial) showing that sorafenib improved
3 380 S. Bracarda et al. / Critical Reviews in Oncology/Hematology 82 (2012) Fig. 1. Incidence of adverse events due to sorafenib over the time. Adapted with permission from Hutson et al. [12]. survival and time to radiologic progression in patients with hepatocellular carcinoma (HCC), led to its approval in the treatment of advanced HCC [1,9,11]. Clinical trial data on the use of sorafenib monotherapy in the clinical practice show that the drug is generally well tolerated with a manageable adverse event profile. However, as with other tyrosine kinase inhibitors (TKIs), sorafenib causes a range of side effects including: dermatological, constitutional (fatigue, weight loss), gastrointestinal (diarrhea, nausea, vomiting, constipation), cardiovascular (mainly hypertension), pain and pulmonary events [1,11]. In most cases adverse events are grade 1 2 severity and decrease over time [12] (Fig. 1). Interestingly, observations from clinical trials and clinical practice suggest that adverse events present early in the course of treatment and there is a lack of unexpected adverse events and cumulative toxicity with the long-term use of sorafenib [13]. However the precise mechanism for this effect remains to be elucidated. 3. Sorafenib-related cutaneous events Due to their higher frequency and negative impact on quality of life, dermatological events probably represent the main problem in the care of sorafenib-treated patients. Eruptions affecting the hands and feet, commonly referred to as the hand-foot skin reaction (HFSR), are frequently described with sorafenib. Successful management of the HFSR requires good prior knowledge of the phenomenon as well as a skilled therapeutic approach [13]. The incidence of cutaneous adverse events in phases I, II and III sorafenib clinical trials in RCC and HCC ranges from 8 to 66% (Table 1) [1,11,14 17]. Other targeted therapies have similar cutaneous side effects with differences in percentages and severity [18]. Dermatological reactions of varying types are ranked among the most common adverse events with the three VEGFR TKIs currently approved sunitinib, sorafenib, and pazopanib, including HFSR with sunitinib and sorafenib and a high frequency of rash/desquamation with sorafenib. The exact pathogenic mechanism of these dermatological events is still unclear, but a number of hypotheses have been proposed [1,19 22]. One initial theory suggested that tyrosin kinase inhibition may affect keratinocyte proliferation and differentiation. Keratinocytes are high proliferation cells in the epidermis that constitute an essential barrier against outside/environmental injuries and prevent water loss from the body. Histological specimens from patients with HFSR highlight keratinocyte damage, the presence of intracytoplasmic eosinophilic bodies and vacuolar degeneration eventually leading to necrosis [22,23]. TKIs such as sorafenib may therefore indirectly interfere with normal skin function. Another theory is based on the observation that the majority of cutaneous adverse events occur in areas of microtrauma such as the scalp, mouth, nails, hands and feet. By blocking vascular development through VEGF and PDGFR-, the microvessels in these areas may be altered in some way that the renewal process cannot function properly [19]. The impairment of homeostatic mechanism regulating skin inflammatory responses has also been investigated by Pastore et al. [24]. Epidermal growth factor receptor (EGFR)- dependent ERK1/2 activity in keratinocytes takes part in a homeostatic mechanism that regulates epidermal involvement in the inflammatory response and confirms the role of kinase inhibition as a potential target for manipulating inflammation in the skin. Because EGFR inhibition represents an effective antitumour treatment strategy the activity due to EGFR inhibition may also rely on a stronger recruitment of inflammatory cells and hence a more pronounced antitumour immune response. We present here a summary of existing evidence regarding the most common events for which a dermatological treatment is required. We did not include other skin side effects (for example alopecia) where dermatological treatment is not required/or is not appropriate Hand-foot skin reaction Hand-foot skin reaction (HFSR), the most frequent event occurring in up to 62% of patients, is that which requires the
4 S. Bracarda et al. / Critical Reviews in Oncology/Hematology 82 (2012) Table 1 Incidence of different cutaneous events induced by sorafenib. Type of event Description All grades (%) Grade 3 (%) Grade 4 (%) Hand-foot skin reaction (HFSR) Erythema or blisters on friction/pressure sites a Erythema Diffuse skin redness with or without itching Itching Itching particularly of the scalp Follicular rash Face and trunk papular-pustular folliculitis Xerosis Pathological skin dryness with or without itching Stomatitis Mouth inflammation From references [1,8,10,13,14,15,16]. Not applicable to HFSR. Table 2 Severity of hand-foot skin reaction (according to common terminology criteria for adverse events, CTCAE v3.0). Grade Description 1 Small skin alterations or dermatitis (e.g. erythema) without pain 2 Skin alterations (exfoliation, small blisters, bleeding, edema) or pain not interfering with normal functions 3 Ulcerative dermatitis or skin alterations with pain interfering with normal functions most care and attention by physicians. Although it is not lifethreatening HFSR, which occurs mainly in the early period of sorafenib treatment, considerably affects the quality of life of patients and reduces their ability to carry out everyday activities. Where possible steps should be taken to prevent it occurring and when it manifests it should be carefully managed to reduce pain, risk of infection, and patient discomfort (subjective or objective), while at the same time avoiding the need to discontinue/reduce the prescribed dosage. In patients treated with sorafenib, the overall incidence of HFSR (grades 1 3) ranges from 18 to 62%. Severe reactions occur less frequently with 4 13% classified as grade 3 (Table 2). These incidences are in line with those observed with other TKIs. HFSR usually occurs two weeks after treatment is started. The first signs are redness and edema, in some cases associated with a burning sensation in the palms of the hands, mainly in the folds between the phalanx joints. Some patients with untreated more severe reactions, develop blisters which can burst and discharge serous fluid. The blisters in HFSR appear characteristically in areas of pressure where reactive hyperkeratosis is present and as such differ from classic hand-foot syndrome (HFS). Classic HFS, also termed acral erythema or palmar-plantar erythrodysesthesia, occurs with various chemotherapeutic agents including cytarabine, capecitabine, doxorubicin hydrochloride, and fluorouracil, while sorafenib-induced HFSR, more frequently than classic HFS, is associated with palmar and/or plantar hyperkeratosis [25]. At the site of the blister, a rose-colored area surrounded by a dry horny layer remains. In rare cases this is accompanied by an intense burning sensation, the entire palm of the hand becomes red and the horny layer becomes detached (corneolysis). In patients with re-existing foot problems (flat feet, hallux valgus, tendinous retractions, osteoporosis, obesity), at areas of high pressure an excess of horny layer (hyperkeratosis) is produced which gives rise to a horny patch or callosity. The presence of the horny layer on the sole of the foot indicates the area where the subject concentrates his bodyweight. In patients with existing callosities, erythemas and blisters can develop following treatment with sorafenib. When the patient walks and puts pressure on this area binding between the horny layer and the epidermis becomes defective and blisters develop. If treatment is delayed superficial erosion can develop. Sub-corneous blisters occur as a result of desmosome impairment binding between keratocytes in the upper layers. Keratocytes of the superficial layers of the epidermis undergo an involutional process losing the bindings with the horny layer which then detaches. The fact that blisters occur only at sites under pressure suggests that such forces are responsible for the mechanical detachment of the horny layer [26]. Histology of the bulla frequently shows upper epidermis keratinocytes fluctuating in the serous medium without evidence of junctions and the horny layer detached from the epidermis (Fig. 2) Erythema Erythema is usually mild (grades 1 and 2) and accounts for 15% of cutaneous reactions (Table 2). It tends to occur from the second or third week of treatment as an erythematous exanthema without specific characteristics, very often confined to the face, trunk and at times is associated with mild itching. Fig. 2. Achantholytic keratinocytes and cleavage of horny layer. Photograph provided and reproduced with the kind permission of Professor Monti.
5 382 S. Bracarda et al. / Critical Reviews in Oncology/Hematology 82 (2012) Itching Two types of itching are observed: one dependent, one independent on skin dryness with an overall incidence of 8 19% for all grades and <1% for grades 3 and 4. Itching independent of skin dryness appears early in the course of treatment and occurs mainly on the scalp. It is thought to be due to excretion of drug metabolites through the sudoriparous glands which are highly diffuse in the scalp [23] Follicular rash The incidence of follicular rash ranges from 11 to 66% for all grades and from 0.7 to 2% for grades 3 and 4. The follicular rash seen with sorafenib treatment is similar to that seen with anti-egf receptor inhibitors and is caused by an acute inflammation of the pilosebaceous follicle. Follicular rash can be predominantly papular-erythematous or predominantly papular-pustular with the face, scalp and upper trunk the sites most involved. Follicular rash is very debilitating as it causes itching, burning and because it is difficult to hide prevents the patient from carrying out every day activities Xerosis or skin dryness The incidence of xerosis grades 1 and 2 ranges from 8 to 23% no grade 3 or 4 have been reported. It is in the main due to reduced water retention in the horny layer which causes desquamation sometimes resembling dandruff. Often skin dryness causes an unpleasant itching sensation Keratocanthoma (KA) and squamous cell carcinoma (SCC) The development of KA and SCC in patients treated with sorafenib has been reported by Arnault et al.: 13 patients developed rapidly growing cutaneous squamous cell proliferation, possibly due to an impairment of skin immunosurvelliance associated with sorafenib treatment, even without a clear cause effect relationship [27]. 4. Recommendations for the prevention and management of sorafenib-related cutaneous reactions Management of cutaneous events with sorafenib should be based on the expertise and practical knowledge of the entire mutlidiscipinary team including oncologists, dermatologists and nurses who are in a position to identify adverse events in a timely manner and to treat with systemic therapy as necessary Hand-foot skin reaction Effective prevention of HFSR begins with a complete evaluation of the patient. Details of the patient s occupation should be noted, for example, if the patient does manual Table 3 Prevention measures. Hand prevention 1. Carefully inform the patient about the hand-foot skin reaction 2. Avoid, whenever possible, carrying heavy loads 3. Keep skin moisturized, wash hands with non-foaming cleansing creams and avoid normal soap 4. After each wash, apply an emollient cream to soften the horny layer Feet prevention 1. Clearly inform the patient about the hand-foot skin reaction 2. Evaluate the crucial plantar pressure points usually corresponding to callosities 3. In the evening apply glycolicsalicylic peeling cream on the plantar hyperkeratotic areas to keep skin soft 4. Recommend the use of comfortable shoes which do not exert pressure on foot and if possible with a latex insole to reduce plantar pressure 5. Wash the foot with non foaming cleansing creams instead of normal soap to keep skin soft 6. After washing, apply zinc oxide and magnesium silicate lenitive cream without vaseline to absorb sweat and reduce the friction 7. Wear perspiring socks without seams if possible labor it is more likely that sub-horny blisters will develop. Likewise, the feet should be carefully examined for the presence of pre-existing horny callosities and/or abnormal plantar pressure areas (Table 3). If, in spite of preventive measures, HFSR grade 1 occurs the following are recommended: Hands at the first onset of redness/sensation of burning where possible manual labor should be stopped and a zinc oxide and magnesium silicate lenitive cream without vaseline should be applied. Feet at the first onset of redness/sensation of burning preventive measures 4, 5, 6, 7 outlined in Table 3 should be initiated. If grades 2 and 3 lesions occur despite preventative measures the following are recommended (Appendix 1): Fluid inside the blister should be aspirated (using a needle from a 10/20 ml disposable syringe) to prevent growth of bacteria/infection. Insert the needle into the blister and aspirate or, after making a small opening with the needle, squeeze the blister with gauze to remove fluid. The area should be disinfected with a 0.2% solution of benzalkonium chloride (Appendix 2). After the blister is burst, medicate with a PEG-based cicatrizing ointment it is not necessary to bandage. If the horny layer covering the blister is dry and becomes detached it can be removed by cutting the edges. The skin below regenerates the horny layer and heals within 1 2 weeks. Avoid antibiotics Erythema If no other signs of cutaneous or systemic toxicity are observed, specific safety measures are not necessary other
6 S. Bracarda et al. / Critical Reviews in Oncology/Hematology 82 (2012) than symptomatic medication. In general erythema does not itch and should be treated with zinc oxide and magnesium silicate lenitive cream without vaseline (Appendix 1). The use of corticosteroids should be restricted to severe cases as they can mask the progression of erythema and/or other adverse events. In addition, it should be remembered that the erythema may be caused by concomitant medications (e.g. paracetamol) Itching Treatment of itching is symptomatic. Normally it cannot be treated topically and systemic therapy is necessary. Although no scientific rationale exists oral anti-histamines are considered to be the drugs of first choice with the potential use of steroids in selected cases Follicular rash As follicular rash following sorafenib is very similar to that seen with anti-egf receptor inhibitors, treatment is the same in both cases a cold compress of potassium permanganate % solution as an astringent anti-inflammatory followed by application of 2% sulfo-salicylic cream without vaseline. This reduces the erythema/pruritus complex as well as reducing pigmentation. Currently the use of antibiotics is not recommended (Appendix 2) Xerosis or skin dryness Xerosis or skin dryness should be managed as follows: If possible take showers instead of baths and avoid rubbing the skin vigorously. Use non-foaming cleansing cream instead of soap or shower-gel. Apply polydecene-based highly emollient ointment after showering to restore water content in the horny layer (Appendix 2) KA and SCC Patients treated with sorafenib should be examined regularly because they carry an increased risk of KA and SCC proliferation. Lesions should be surgically removed without interrupting the treatment, and there is no evidence of relapse after the removal; in patients with multiple, unresecatble lesions, an interruption of sorafenib may be considered, as it may likely lead to a spontaneous resolution of the symptoms [27 29]. psychological distress to patients but can also have a negative effect on outcome as dose reductions or treatment discontinuations may be necessary. Although data from sorafenib pivotal comparative trials and from expanded access trials show no differences in the incidence and severity of cutaneous adverse events between younger and older patients, the SWG believes that particular attention should be paid to elderly patients treated with sorafenib [30 32]. In this patient group cutaneous adverse events may be complicated by the presence of comorbidities. In addition, these patients are often imunocompromised and may need to take a range of concomitant medications. Sorafenib represents an important advance in the treatment of RCC and HCC two neoplastic diseases until a few years ago considered unresponsive to conventional chemotherapy and in the near future other tumor types could benefit from this drug. The major challenge for physicians is to develop ways to detect, prevent and effectively manage the cutaneous treatment-related adverse events in order to: allow the recommended dose of sorafenib to be administered; avoid the need for dose reductions; preclude temporary/permanent treatment discontinuation. The recommendations set out in this report in terms of early diagnosis, prevention and patient care present a practical and easy-to-implement method for physicians to care for their patients receiving sorafenib. Our goal is to prevent (where possible), or to effectively treat sorafenib-related cutaneous events without the need for additional drugs thereby reducing patient discomfort and increasing compliance. It is now generally accepted that cutaneous events represent a necessary evil in cancer treatment and they have been compared with neutropenia caused by conventional chemotherapeutic regimens, which if not controlled can also lead to dose reduction/discontinuation [33]. As it seems that cutaneous events cannot be completely prevented, our recommendation is that they should be managed in the best possible way starting from a complete review of any predisposing factors of the patient, through to early detection of symptoms and the timely introduction of treatment according to the grade and duration of skin reactions. Interestingly, retrospective studies in patients treated with sorafenib [34] and erlotinib [35] suggest that there may be a correlation between the onset of skin rash and an improved clinical outcome. Prospective trials are needed to determine if cutaneous reactions can be indeed considered as a clinical surrogate marker for antitumor activity. 5. Conclusions Management of sorafenib-related cutaneous reactions, including HFSR represents a major challenge for physicians. These complications not only cause physical and Authors contributions Sergio Bracarda, Enzo Maria Ruggeri, Marcello Monti contributed in conception and design of the study. Sergio Bracarda, Enzo Maria Ruggeri, Marcello Monti, Marco
7 384 S. Bracarda et al. / Critical Reviews in Oncology/Hematology 82 (2012) Merlano, Alessandro D Angelo, Francesco Ferraù, Enrico Cortesi, Armando Santoro provided study materials. Sergio Bracarda, Enzo Maria Ruggeri, Marcello Monti, Marco Merlano, Alessandro D Angelo, Francesco Ferraù, Enrico Cortesi, Armando Santoro have collected and assembled the data. Data analysis and interpretation done by Sergio Bracarda, Enzo Maria Ruggeri, Marcello Monti, Marco Merlano, Alessandro D Angelo, Francesco Ferraù, Enrico Cortesi, Armando Santoro. Sergio Bracarda, Enzo Maria Ruggeri, Marcello Monti, Marco Merlano, Alessandro D Angelo, Francesco Ferraù, Enrico Cortesi, Armando Santoro prepared the manuscript. Final approval of manuscript given by Sergio Bracarda, Enzo Maria Ruggeri, Marcello Monti, Marco Merlano, Alessandro D Angelo, Francesco Ferraù, Enrico Cortesi, Armando Santoro. Conflict of interest statement Employment/leadership position: None. Intellectual property rights/inventor or patent holder: None. Consultant/advisory role: Sergio Bracarda, Bayer Healthcare, Pfizer, Novartis, GSK. Enzo Maria Ruggeri, Bayer Healthcare, GSK, Pfizer. Honoraria received directly from commercial interest or their agents: Sergio Bracarda, Novartis. Research funding/contracted research: None. Ownership interest: None. Expert testimony: None. Reviewers Dr. Giuseppe Procopio, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. Dr. Jann Luebbe, Clinique de Genolier, Dermatology Department, Route du Muids, CH-1272 Genolier, Switzerland. Prof. Francesco Di Costanzo, Azienda Ospedaliero Universitaria Careggi, Department of Oncology, Via Pieraccini 17, Florence, Italy. Acknowledgments Editorial assistance was provided by Luca Giacomelli, PhD, of Content Ed Net; this assistance was funded by Bayer Italy. Appendix 1. Recommendations for the management of treatment with sorafenib. Skin toxicity criteria for drug-dose reductions and treatment discontinuation (any adverse event). Toxicity a Drug administration management For the current cycle For the next cycle Grade 1 Appearance No modifications No modifications Grade 2 1st appearance Discontinuation until improvement to grade 1 No modifications 2nd appearance Discontinuation until improvement to grade 1 Consider drug dose reduction 3rd appearance Discontinuation until improvement to grade 1 Consider drug dose reduction 4th appearance Treatment withdrawal Grade 3 1st appearance Discontinuation until improvement to grade 1 Consider drug dose reduction b 2nd appearance Discontinuation until improvement to grade 1 Consider drug dose reduction 3rd appearance Treatment withdrawal a Toxicity evaluations according to CTCAE v3.0 ( CTCAE = common terminology criteria for adverse events. b For patients needing drug-dose reduction following grade 3 rash or hand-foot skin reaction, drug dose can be increased again to the starting dose provided that after a complete cycle at reduced dose no grade 1 event has been observed. Suggested drug-dose modifications of sorafenib in case of hand-foot skin reaction. Toxicity a Drug-dose modification Grade 1 Any Start immediately with prevention/supporting measures and continue treatment Grade 2 1st appearance Immediately start with prevention/supporting measures and consider drug dose reduction to 400 mg/day for 28 days If after drug dose reduction toxicity decreases to grade 1, return to full dose If after drug dose reduction toxicity does not revert to grade 1, discontinue treatment for a minimum of 7 days until toxicity decreases to grade 0 1 If after discontinuation toxicity reverts to grade 1, start treatment again at the reduced dose of 400 mg/day for 28 days. If at the reduced dose grade 0 1 toxicity continues, return to full dose after 28 days 2nd/3rd appearance As for the 1st appearance, but start treatment again permanently at the reduced dose of 400 mg/day 4th appearance The decision about treatment withdrawal should be based on clinical evaluation and the patient s wishes
8 S. Bracarda et al. / Critical Reviews in Oncology/Hematology 82 (2012) (Continued ) Toxicity a Drug-dose modification Grade 3 1st appearance Start immediately with prevention/supporting measures and discontinue treatment for at least 7 days If after drug dose reduction toxicity decreases to grade 1, start treatment again at the reduced dose of 400 mg/day for 28 days If at the reduced dose grade 1 toxicity continues, return to full dose after 28 days 2nd appearance As for the 1st appearance, but start treatment again permanently at the reduced dose of 400 mg/day 3rd appearance The decision regarding treatment withdrawal should be based on clinical evaluation and the patient s wishes a Toxicity evaluations according to CTCAE v3.0 ( CTCAE = common terminology criteria for adverse events. Appendix 2. Suggested products for the treatment of skin reactions. 1. Non foaming cleansing cream containing taurate and sarcosinate detergents 2. Polydecene based highly emollient ointment 3. Glycolic salicylic peeling cream 4. Zinc oxide and magnesium silicate lenitive cream without vaseline 5. Benzalkonium chloride 0.2% aqueous solution 6. Cicatrizing PEG and allantoin ointment 7. Potassium permanganate (tablet 250 mg) a 8. Sulfosalicylic cream without vaseline For external use compress only. a To prepare the potassium permanganate solution, dissolve a 250 mg tablet in 2 L of boiling water, cool and keep it in a dark glass bottle. References [1] Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356: [2] Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356: [3] Di Lorenzo G, Porta C, Bellmunt J, et al. Toxicities of targeted therapy and their management in kidney cancer. Eur Urol January 14 [Epub ahead of print]. [4] Kirkali Z. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use. BJU Int 2011, doi: /j x x. January 20 [Epub ahead of print]. [5] Porta C, Paglino C, Imarisio I, et al. Uncovering Pandora s vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin Exp Med 2007;7(December (4)): [6] Chu D, Lacouture ME, Fillos T, Shenhong WU. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol 2008;47: [7] Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol 2011;78: [8] Monti M, Motta S. Clinical management of cutaneous toxicity of anti- EGFR agents. Int J Biol Markers 2007;22(1 (Suppl. 4)):S [9] Bracarda S, Caserta C, Sordini L, et al. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. Ann Oncol 2007;18(June (Suppl. 6)):vi22 5. [10] Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7(October (10)): [11] Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). N Engl J Med 2008;359: [12] Hutson TE, Bellmunt J, Porta C, et al. Long-term safety with sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET. Eur J Cancer 2010;46: [13] Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. BJU Int 2011 April, doi: /j x x. [14] Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12: [15] Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24: [16] Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24: [17] Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10(June (5)): [18] Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10(January (1)): [19] Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13: [20] Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6(July (7)): [21] Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27(July (20)): [22] Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009;77(5), [23] Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 2008;158: [24] Pastore S, Mascia F, Mariotti F, Dattilo C, Mariani V, Girolomoni G. Expression and skin inflammation ERK1/2 regulates epidermal chemokine and skin inflammation. J Immunol 2005;174: [25] Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144(7):
9 386 S. Bracarda et al. / Critical Reviews in Oncology/Hematology 82 (2012) [26] Cirillo N, Prime SS. Desmosomal interactome in keratinocytes: a systems biology approach leading to an understanding of the pathogenesis of skin disease. Cell Mol Life Sci 2009;66: [27] Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27(August (23)):e [28] Kong HH, Cowen EW, Azad NS, et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007;56(January (1)): [29] Jantzem H, Dupre-Goetghebeur D, Spindler P, Merrer J. Sorafenibinduced multiple eruptive keratoacanthomas. Ann Dermatol Venereol 2009;136(December (12)): [30] Eisen T, Oudard S, Szczylik C, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008;100(October (20)): [31] Bukowski RM, Stadler WM, McDermott DF, et al. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology 2010;78(5-6): [32] Beck J, Procopio G, Bajetta E, et al. Final results of the European advanced renal cell carcinoma sorafenib (EU-ARCCS) expandedaccess study: a large open-label study in diverse community settings. Ann Oncol February 15 [Epub ahead of print]. [33] Di Maio M, Gridelli C, Gallo C, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005;6(September (9)): [34] Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist 2010;15: [35] Cobo M, Cardenal F, Insa A, et al. Skin as a surrogate marker of efficacy in patients with non-small cell lung cancer treated with erlotinib. J Clin Oncol 2007:7602 (ASCO Annual Meeting Proceedings Part I, vol. 25, No. 18s). Biographies Sergio Bracarda is currently the director of the medical oncology Unit, Department of Oncology, Ospedale San Donato, Azienda USL8, Arezzo. Previously he was a senior oncologist at the Medical Oncology Division, Santa Maria della Misericordia Hospital, Perugia, Italy, from where he was appointed section chief of Oncology-Urology Tumors, and contract professor for the Schools of Specialization in Oncology and Urology at the University of Perugia. His main research interest is genito-urinary oncology, and in particular prostate cancer and advanced renal cell carcinoma, CNS tumors, targeted anticancer therapies and treatment approaches that combine biological agents with traditional chemotherapy or immunotherapy. Dr. Bracarda specialized in medical oncology at the Sacred Heart Catholic University of Rome, Italy, and in urology at the University of Perugia and has published 52 publications in peer-reviewed medical journals, more than 600 abstracts, and a number of text book chapters. Enzo Maria Ruggeri is director of the Medical Oncology Division, Ospedale Belcolle, Viterbo, Italy. He specialized in medical oncology at the La Sapienza University, Rome. His main current research interests are genitor-urinary and head-neck oncology. Marcello Monti is the director of the Dermatology Division in the Istituto Clinico Humanitas (ICH) in Rozzano (Milan), Italy and lecturer in Dermatology at the Specialisation Schools of Geriatrics, Plastic Surgery and Dermatology. He specialized in dermatology and venereology and subsequently in infective and parasitic diseases at Milan University. Marco Merlano is head of the Translational Laboratory, Medical Oncology Units and Department of Clinical Oncology at Santa Croce General Hospital, Cuneo and contract professor at the post-graduate School of Medical Oncology in Turin, Italy. His current main research interests are head neck and genitor-urinary oncology. Alessandro D Angelo is junior oncologist of the Medical Oncology Division, Ospedale Civico San Vincenzo, Taormina (ME), Italy. His current research interest is genitorurinary oncology. Francesco Ferraù is director of the Medical Oncology Division, Ospedale Civico San Vincenzo, Taormina (ME), Italy. His main research interests are breast and genitorurinary oncology. Enrico Cortesi is director of the Oncology Unit, Policlinico Umberto I and Professor of Medical Oncology at La Sapienza University, Rome, Italy. His main research interests are supportive care and genito-urinary oncology. Armando Santoro is director of the Medical Oncology Division, Humanitas Cancer Center Istituto Clinico Humanitas (ICH), Rozzano (Milan), Italy. He specialized in Clinical and Laboratory Hematology at the University of Rome and in Oncology at the University of Genoa, Italy. Genitor-urinary oncology is among his current research interests.
Skin Side Effects U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A
Skin Side Effects Christiane Thallinger, M D U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A Targets Substances 1 Multi Kinase Inhibitors
More informationMultikinase inhibitors: Multikinase inhibitors: Regorafenib skin toxicity. Cutaneous side effects of multikinase-inhibitors and their management
TARGETED THERAPIES AND THEIR CUTANEOUS TOXICITIES Brussels, 14/1/2017 Cutaneous side effects of multikinase-inhibitors and their management Siegfried Segaert Dermatology Dept. Uinversity Hospital Leuven
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: SORAfenib Therapy INDICATION ICD10 Regimen Code Treatment of hepatocellular carcinoma (HCC). C22 00294a CDS C64 00294b CDS Treatment of patients with advanced renal cell carcinoma
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationEfficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment
Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment Hisanori Suzuki 1),2), Toshiro Suzuki 1),2), Osamu Ishizuka 1),2), Osamu Nishizawa 1),2),
More informationCutaneous reactions to targeted therapies. Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017
Cutaneous reactions to targeted therapies Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017 Disclosures I have no relevant disclosures Papulopustular Eruption
More informationCurrent Status of Studies on Targeted Therapy for Renal Cell Carcinoma
294 Chin J Clin Oncol (2008) 5: 294~298 DOI 10.1007/s11805-008-0294-x Current Status of Studies on Targeted Therapy for Renal Cell Carcinoma Shaoqi Wang 1 Shaoxiang Wang 2 Juan Wang 1 1 Department of Oncology,
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationNexavar in advanced HCC: a paradigm shift in clinical practice
Nexavar in advanced HCC: a paradigm shift in clinical practice Tim Greten Hanover Medical School, Germany Histopathological progression and molecular features of HCC Chronic liver disease Liver cirrhosis
More informationNursing s Role in the Management of New Oral Chemotherapy Agents
Nursing s Role in the Management of New Oral Chemotherapy Agents Mechelle Barrick BSN, RN, OCN, CCRP Clinical Research Nurse Coordinator Greater Baltimore Medical Center mbarrick@gbmc.org THE NURSES ROLE
More informationHand Foot Skin Reaction is Associated with the Clinical Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Sorafenib
Original Article Japanese Journal of Clinical Oncology Advance Access published August 15, 2013 Jpn J Clin Oncol doi:10.1093/jjco/hyt110 Hand Foot Skin Reaction is Associated with the Clinical Outcome
More informationManagement of side-effects of anti-angiogenetic inhibitors in treating HCC
Management of side-effects of anti-angiogenetic inhibitors in treating HCC Massimo Di Maio Clinical Trials Unit National Cancer Institute, Napoli dimaiomax@libero.it BCLC staging system and treatment strategy
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More information17/01/2017. Use of kinase inhibitors in oncology practice. Multikinase inhibitors. Sunitinib (Sutent )targets. Many more sunitinib kinase targets (42)
Multikinase inhibitors Use of kinase inhibitors in oncology practice Prof Jacques De Grève, UZ Brussel Inhibit multiple intracellular and cell surface kinases Tyrosine or serine-threonine kinases Multitargeting
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced
More informationSorafenib in the management of metastatic renal cell carcinoma
SORAFENIB IN THE MANAGEMENT OF METASTATIC RCC UROLOGIC ONCOLOGY Sorafenib in the management of metastatic renal cell carcinoma C. Guevremont b s c, C. Jeldres m d, P. Perrotte m d, and P.I. Karakiewicz
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationSustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma
JOURNAL OF CASE REPORTS 2015;5(1):280-284 Sustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma Chanchal Goswami, Aditi Mandal B. P. Poddar Hospital & Medical Research
More informationCLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12
Page: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationTherapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis
EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 2275-2280, 2015 Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis QINXIANG TAN 1*,
More informationAngiogenesis Targeted Therapies in Renal Cell Carcinoma
Angiogenesis Targeted Therapies in Renal Cell Carcinoma John S. Lam, MD Department of Urology David Geffen School of Medicine University of California-Los Angeles Patient Case CC: Abdominal pain VS: T
More informationClinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma
european urology supplements 7 (2008) 593 600 available at www.sciencedirect.com journal homepage: www.europeanurology.com Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced
More informationSubject: Axitinib (Inlyta ) Tablets
09-J1000-67 Original Effective Date: 05/15/12 Reviewed: 12/12/18 Revised: 01/15/19 Subject: Axitinib (Inlyta ) Tablets THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: SUNitinib 50mg Therapy INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of unresectable and/or metastatic malignant gastrointestinal C26 00325a CDS stromal tumour (GIST)
More informationBreast Pathway Group Docetaxel in Advanced Breast Cancer
Breast Pathway Group Docetaxel in Advanced Breast Cancer Indication: First-line palliative treatment, with or without trastuzumab, for advanced breast cancer in patients for whom an anthracycline is not
More informationIl treatment plan nella terapia sistemica dell epatocarcinoma
Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationUpdates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash. Outline. Signal Transduction
Updates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash Siu-Fun Wong, PharmD, FASHP, FCSHP Associate Professor of Pharmacy Practice Western University of Health
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationDevelopment of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib
Hussain et al. BMC Endocrine Disorders 2013, 13:29 CASE REPORT Open Access Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib Syed Zubair
More informationCapecitabine plus Docetaxel in Advanced Breast Cancer
Capecitabine plus Docetaxel in Advanced Breast Cancer Indication: Palliative therapy in Anthracycline-Pretreated Patients with Advanced Breast Cancer Regimen details: Docetaxel 75mg/m 2 IV D1 Capecitabine*
More informationDescription Sorafenib (Nexavar) is an oral medication used to treat certain types of cancer. It works by blocking the growth of cancer cells.
Medication Policy Manual Policy No: dru134 Topic: Nexavar, sorafenib Date of Origin: March 10, 2006 Committee Approval Date: November 13, 2014 Next Review Date: November 2015 Effective Date: December 1,
More informationLiposomal Doxorubicin (CAELYX) Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Liposomal Doxorubicin (CAELYX) Gynaecological Cancer PROCTOCOL REF: OPHAGYNCAE (Version No: 1.0) Approved for use in: Advanced ovarian cancer second/third line treatment
More informationBreast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer
Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Indication: Neoadjuvant therapy for high risk and fit breast cancer patients suitable for
More informationKidney Cancer. Version February 6, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines )
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Kidney Cancer Overall management of Kidney Cancer from diagnosis through recurrence is described in the full NCCN Guidelines for Kidney
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationpan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma
pan-canadian Oncology Drug Review Stakeholder Feedback on a pcodr Request for Advice Axitinib (Inlyta) for Metastatic Renal Cell Carcinoma Pfizer Canada Inc. June 29, 2017 3 Stakeholder Feedback on a pcodr
More information17/01/2017. ckit NRAS BRAF MEK ERK. ANTITUMOR IMMUNE RESPONSE PROLIFERATION
BRAF inhibitors: vemurafenib (Zelboraf ) dabrafenib (Tafinlar ) Universitair Ziekenhuis Gent MEK inhibitors: cobimetinib trametinib(mekinist ) selumetinib CUTANEOUS SIDE EFFECTS OF BRAF-INHIBITORS Lieve
More informationLung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC) Indication: First line palliative therapy for previously untreated Stage IIIB or IV NSCLC patients Regimen details: Docetaxel
More informationIdentifying and managing dermatologic toxicities associated with EGFR-inhibitor therapy. An educational resource for healthcare professionals
Identifying and managing dermatologic toxicities associated with EGFR-inhibitor therapy An educational resource for healthcare professionals What to expect from EGFR-inhibitor therapy The goal of EGFR-inhibitor
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationAvailable at American Society of Clinical Oncology: 3
Addition of Tarceva (erlotinib) to Nexavar (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial Wayne, NJ, South San Francisco,
More information蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )
蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationBackgrounder. 1. What are targeted therapies? 2. How do targeted therapies work?
Backgrounder TARGETED THERAPIES FOR CANCER 1. What are targeted therapies? 2. How do targeted therapies work? 3. What are some of the different types of targeted therapy? 4. What are the potential benefits
More informationSorafenib for the treatment of advanced hepatocellular carcinoma
DOI: 10.3310/hta14suppl1/03 Health Technology Assessment 2010; Vol. 14: Suppl. 1 Sorafenib for the treatment of advanced hepatocellular carcinoma M Connock, 1 J Round, 2 S Bayliss, 1 S Tubeuf, 2 W Greenheld
More informationcontinuing education Prevention and management of hand-foot syndromes Jia Conway, DNP, FNP-BC, NP-C
continuing education educational objectives After participating in this activity, clinicians should be better able to Identify a novel anticancer therapy that contributes to hand-foot syndromes and hand-foot
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationFoot Care. Taking steps towards good FOR AT-RISK FEET. HIGH RISK of developing serious. Person with Diabetes
Taking steps towards good Person with Diabetes Foot Care FOR AT-RISK FEET Your healthcare professional has found that as a person with Diabetes your feet have a HIGH RISK of developing serious problems
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationFoot Care. Taking steps towards good FOR AT-RISK FEET. HIGH RISK of developing serious. Person with Diabetes
Taking steps towards good Person with Diabetes Foot Care FOR AT-RISK FEET Your healthcare professional has found that as a person with Diabetes your feet have a HIGH RISK of developing serious problems
More informationCamillo Porta S.C. di Oncologia Medica Università degli Studi di Pavia & I.R.C.C.S. Fondazione Policlinico San Matteo di Pavia
Keynote Lecture: Immunotherapy in GU cancer: where are we, and where are we going? Camillo Porta S.C. di Oncologia Medica Università degli Studi di Pavia & I.R.C.C.S. Fondazione Policlinico San Matteo
More informationBreast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer
Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment for patients in whom anthracyclines are contraindicated or inappropriate Regimen
More information(212) Investors Contact: Ryan Crowe (212)
For immediate release: February 5, 2014 Media Contact: Sally Beatty (212) 733-6566 Investors Contact: Ryan Crowe (212) 733-8160 Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies
More informationRABEPRAZOL 10mg and 20mg Gastro-resistant Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets RABEPRAZOLE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet
More informationSafety Considerations and Side Effect Management with Tyverb (Lapatinib)
Safety Considerations and Side Effect Management with Tyverb (Lapatinib) Prescribing information can be found at the end of the presentation Date of prep: 19-Sep-2011 UK/LPD/0226a/11 HER2 (ErbB2)-positive
More informationAxitinib in renal cell carcinoma: now what do we do?
Renal Cell Carcinoma Axitinib in renal cell carcinoma: now what do we do? Ian D. Davis Monash University Eastern Health Clinical School, Level 2, Box Hill, Victoria 3128, Australia Correspondence to: Ian
More informationScottish Medicines Consortium
Scottish Medicines Consortium sorafenib 200mg tablets (Nexavar ) (No. 321/06) Bayer Plc 6 October 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationAfatinib (Giotrif ) Your treatment Your doctor has prescribed you a treatment called afatinib (Giotrif ) which is a tablet and is taken orally.
Afatinib (Giotrif) Afatinib (Giotrif ) This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer
More informationTherapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic
Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic Amy Olson, MD, MSPH Associate Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO
More informationMedical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce
Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce
More informationNovel Molecular Molecular Therapies In Hepatocarcinoma Prof Eric
Novel Molecular Therapies In Hepatocarcinoma Prof. Eric Raymond Department of Médical Oncology Hôpital Beaujon, Clichy Université Paris 7 Denis Diderot INSERM-U728 eric.raymond@bjn.aphp.fr HCC is a highly
More informationNovel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial 2014-309-00CH1 Presenter: Jifang Gong, Beijing Cancer Hospital Lin Shen 1, Li Zhang 2, Hongyun Zhao 2, Wenfeng Fang 2,
More informationManagement guidelines for dermatologic adverse events (daes)
Management guidelines for dermatologic adverse events (daes) Brian is an Optune patient. A healthcare provider s guide to identifying, preventing, and managing daes for patients using Optune Indications
More informationOral Chemotherapy Nathan Brashear, PharmD Candidate 2017 University of Kentucky College of Pharmacy
Oral Chemotherapy Nathan Brashear, PharmD Candidate 2017 University of Kentucky College of Pharmacy 1 Objectives Identify the more commonly dispensed oral chemotherapy drugs and their indications/dosage
More informationNintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
More informationFoot Care. Taking steps towards good FOR AT-RISK FEET. Person with Diabetes
Taking steps towards good Person with Diabetes Foot Care FOR AT-RISK FEET Your healthcare professional has found that as a person with Diabetes your feet have a LOW RISK of developing serious problems,
More informationMEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc
MEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc * A hypothetical case study of a patient eligible for first-line mcrc therapy. mcrc = metastatic colorectal cancer. WHAT CLINICAL CHARACTERISTICS AFFECT YOUR
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationSequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis
available at www.sciencedirect.com journal homepage: www.europeanurology.com Kidney Cancer Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A
More informationPrimary Care Management of the Kidney Cancer Patient
Primary Care Management of the Kidney Cancer Patient Elaine Lam, MD Mountain States Cancer Conference 2016 November 5, 2016 Learning Objectives 1. Understand the mechanisms of action of currently approved
More informationNivolumab nel carcinoma renale metastatico: esperienza italiana
Nivolumab nel carcinoma renale metastatico: esperienza italiana Ugo De Giorgi Istituto Tumori Romagna IRST IRCCS Meldola on behalf of the Italian EAP RCC Group Real world data from the Italian expanded
More informationLenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059]
Contains AIC Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine [ID1059] Multiple Technology Appraisal Background and Clinical Effectiveness Lead team: Femi Oyebode
More informationLung Pathway Group Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA258 NICE TA162 Locally advanced or metastatic NSCLC as a first line treatment option Positive test for epidermal growth
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationSorafenib for Advanced Hepatocellular Carcinoma
CED-SOS Advice Report 7 ARCHIVED 2012 Sorafenib for Advanced Hepatocellular Carcinoma J. Knox, R. Cosby, K. Chan, and M. Sherman A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationAdverse side effects associated to metronomic chemotherapy
Adverse side effects associated to metronomic chemotherapy Elisabetta Munzone, MD Division of Medical Senology Istituto Europeo di Oncologia Milano, Italy LDM: the optimal biological dose Although there
More informationPhototherapy and Photochemotherapy Treatment (Ultraviolet A [PUVA] and B [UBV])
Origination: 09/27/07 Revised: 08/2/17 Annual Review: 11/2/17 Purpose: To provide Phototherapy and Photochemotherapy Treatment (PUVA and UBV) guidelines for the Medical Department staff to reference when
More informationDOSING AND INFORMATION GUIDE LEAPS AHEAD
DOSING AND INFORMATION GUIDE In patients with WT RAS* mcrc 1 VECTIBIX (panitumumab) LEAPS AHEAD 5.6-month increase in median OS with FOLFOX vs FOLFOX alone 1 Spot the difference. CHOOSE VECTIBIX PRIME
More informationSorafenib (Nexavar ) for hepatocellular carcinoma (HCC)
Sorafenib (Nexavar ) for hepatocellular carcinoma (HCC) Sorafenib (Nexavar ) for hepatocellular carcinoma (HCC) This leaflet is offered as a guide to you and your family. The possible benefits of treatment
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationEUROPEAN UROLOGY 63 (2013)
EUROPEAN UROLOGY 63 (2013) 254 261 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Kidney Cancer Editorial by Axel Bex on pp. 262 264 of this issue Could
More informationCutimed ACUTE Urea-based skin care. Gentle cream mousse a selection for all moisture needs.
Cutimed ACUTE Urea-based skin care Gentle cream mousse a selection for all moisture needs. Cutimed ACUTE Balanced hydration Dry skin is associated with aging, environmental, and medical conditions such
More informationLung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA310 First line treatment option in locally advanced or metastatic NSCLC Positive test for epidermal growth factor receptor
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Stivarga) Reference Number: CP.PHAR.107 Effective Date: 12.01.12 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of
More informationPREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with
BCCA Protocol Summary for Palliative Therapy of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, or Anal Squamous Cell Carcinoma using
More informationREAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO
REAL WORLD PRACTICE: ADJUVANT THERAPY READY FOR PRIME TIME? PRO Alain Ravaud, MD.PhD Bordeaux. France DISCLOSURES Consultant for: Pfizer, Novartis, GlaxoSmithKline, Roche, Bristol-Myers Squibb Institutional
More informationEGFR-TARGETED THERAPIES FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Pocket Guide
EGFR-TARGETED THERAPIES FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Pocket Guide The information in this pocket guide is intended as reference material and should not replace clinical judgment or updated
More informationThe Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma
The Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma Reinhard Dummer, 1 Keith Flaherty, 2 Richard Kefford, 3 Paolo A. Ascierto, 4 Laure Moutouh-de Parseval,
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationEfficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.5.1971 Efficacy and Toxicity of Sunitinib in Egyptian Patients with Metastatic Renal Cell Carcinoma RESEARCH ARTICLE Efficacy and Toxicity of Sunitinib in Metastatic
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of Disease Epidemiology Non-Small Cell Lung Cancer (NSCLC): Non-small cell lung cancer accounts for 85 90% of lung cancers [Reck, 2014] and is the leading
More information